WallStSmart

Agilent Technologies Inc (A)vsMedpace Holdings Inc (MEDP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agilent Technologies Inc generates 170% more annual revenue ($7.23B vs $2.68B). A leads profitability with a 19.6% profit margin vs 17.2%. A appears more attractively valued with a PEG of 1.28. A earns a higher WallStSmart Score of 71/100 (B).

A

Strong Buy

71

out of 100

Grade: B

Growth: 6.7Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 1.99

MEDP

Strong Buy

66

out of 100

Grade: B-

Growth: 8.7Profit: 9.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 1.83
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-73.4%)

Margin of Safety

-73.4%

Fair Value

$74.34

Current Price

$135.44

$61.10 premium

UndervaluedFair: $74.34Overvalued
MEDPSignificantly Overvalued (-50.2%)

Margin of Safety

-50.2%

Fair Value

$282.31

Current Price

$454.25

$171.94 premium

UndervaluedFair: $282.31Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 9.0/10
EPS GrowthGrowth
60.0%10/10

Earnings expanding 60.0% YoY

Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

MEDP4 strengths · Avg: 8.8/10
Return on EquityProfitability
77.0%10/10

Every $100 of equity generates 77 in profit

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Revenue GrowthGrowth
26.5%8/10

Revenue surging 26.5% year-over-year

Areas to Watch

A3 concerns · Avg: 3.7/10
P/E RatioValuation
26.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

MEDP4 concerns · Avg: 3.0/10
P/E RatioValuation
29.4x4/10

Moderate valuation

Altman Z-ScoreHealth
1.834/10

Grey zone — moderate risk

PEG RatioValuation
2.872/10

Expensive relative to growth rate

Price/BookValuation
21.7x2/10

Trading at 21.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on EPS Growth, Operating Margin. Profitability is solid with margins at 19.6% and operating margin at 23.7%. PEG of 1.28 suggests the stock is reasonably priced for its growth.

Bull Case : MEDP

The strongest argument for MEDP centers on Return on Equity, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 20.0%. Revenue growth of 26.5% demonstrates continued momentum.

Bear Case : A

The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.

Bear Case : MEDP

The primary concerns for MEDP are P/E Ratio, Altman Z-Score, PEG Ratio.

Key Dynamics to Monitor

A profiles as a mature stock while MEDP is a growth play — different risk/reward profiles.

A carries more volatility with a beta of 1.26 — expect wider price swings.

MEDP is growing revenue faster at 26.5% — sustainability is the question.

A generates stronger free cash flow (184M), providing more financial flexibility.

Bottom Line

A scores higher overall (71/100 vs 66/100), backed by strong 19.6% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Medpace Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.

Want to dig deeper into these stocks?